title: Complete response to the combination therapy with androgen blockade and somatostatin analogue in a patient with advanced prostate cancer: magnetic resonance imaging with 1H-spectroscopy.
abstract: A 74-yr-old man with prostatic adenocarcinoma underwent magnetic resonance 1H-spectroscopic imaging (1H-MRSI) of the prostate. Based on the results, he was treated with combination therapy using complete androgen blockade (leuprorelin acetate 3.75 mg every 4 wk plus bicalutamide 50 mg daily) and a somatostatin analogue (lanreotide acetate 60 mg every 4 wk). Serum prostate-specific antigen and chromogranin A levels steadily decreased over a 12-mo follow-up period, at which time the patient is alive without disease progression and with a complete objective and symptomatic response.
authors.affiliation: Department of Urology, University La Sapienza, Rome, Italy. sciarrajr@hotmail.com
authors.forename: Alessandro
authors.initials: A
authors.lastname: Sciarra
authors.forename: Valeria
authors.initials: V
authors.lastname: Panebianco
authors.forename: Mauro
authors.initials: M
authors.lastname: Ciccariello
authors.forename: Stefano
authors.initials: S
authors.lastname: Salciccia
authors.forename: Alessandro
authors.initials: A
authors.lastname: Gentilucci
authors.forename: Danilo
authors.initials: D
authors.lastname: Lisi
authors.forename: Roberto
authors.initials: R
authors.lastname: Passariello
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Gentile
authors.forename: Franco
authors.initials: F
authors.lastname: Di Silverio
mesh_terms: D000172:Acromegaly; D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy*; D000368:Aged; D000726:Androgen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage / Q000627:therapeutic use*; D009682:Magnetic Resonance Spectroscopy / Q000379:methods*; D008297:Male; D010456:Peptides, Cyclic / Q000008:administration & dosage / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D012720:Severity of Illness Index; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin; D016729:Leuprolide